NCT06874894View on ClinicalTrials.gov

Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

Enrolling by invitationOBSERVATIONAL
Enrollment

1,100

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2026

Conditions
Fibrillation, Atrial
Trial Locations (1)

06973

Chung-Ang University Hospital, Seoul

All Listed Sponsors
collaborator

Chung-Ang University Gwangmyeong Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Korea University Ansan Hospital

OTHER

collaborator

Kosin University Gospel Hospital

OTHER

collaborator

Keimyung University Dongsan Medical Center

OTHER

collaborator

Yuhan Corporation

INDUSTRY

lead

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

NCT06874894 - Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF) | Biotech Hunter | Biotech Hunter